AVIR — Atea Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $324.03m
- $104.56m
Atea Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Atea Pharmaceuticals, Inc. expected to post a loss of 56 cents a share - Earnings Preview
Atea Pharmaceuticals, Inc. expected to post a loss of 56 cents a share - Earnings Preview
NASDAQ RESUMED AT 07:30 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 06:55 AM
Brief: Atea Pharmaceuticals Completes Patient Enrollment In Phase 3 C-Forward Trial Evaluating Bemnifosbuvir And Ruzasvir For Treatment Of Hepatitis C Virus
Brief: Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-In-Class Profile Of The Regimen Of Bemnifosbuvir And Ruzasvir For The Treatment Of Hepatitis C Virus At Easl Congress 2026
Brief: Atea Pharmaceuticals Reports First Quarter 2026 Financial Results
Atea Pharmaceuticals Q1 net loss widens on higher R&D spending
Atea Pharmaceuticals Q4 net loss widens
Brief: Atea Pharmaceuticals Q4 Basic EPS USD -0.57
Brief: Atea Pharmaceuticals Presents Preclinical Results Of At-587
Brief: Atea Pharmaceuticals Completes Patient Enrollment In North American Phase 3 Trial Evaluating Regimen Of Bemnifosbuvir And Ruzasvir For Treatment Of Hepatitis C Virus
Atea Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Atea Pharmaceuticals Inc expected to post a loss of 45 cents a share - Earnings Preview
Atea Pharmaceuticals Inc expected to post a loss of 45 cents a share - Earnings Preview
Brief: Atea Pharmaceuticals Announces Continued Advancement Of Global Phase 3 Hcv Program
Atea Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Atea Pharmaceuticals Q1 Basic EPS USD -0.4